Vor Biopharma board sees director change as Levin resigns, Zaccardelli named

Vor Biopharma disclosed in a Form 8-K that Andrew Levin, M.D., Ph.D., a member of the Board of Directors, delivered his notice of resignation effective immediately on July 6, 2026.¹ The company noted that Dr. Levin's decision to resign was not the result of any disagreement with the company.¹

The following day, the Board named David Zaccardelli, Pharm.D., to fill the seat left open by Levin's departure, naming him an independent Class II director whose term runs until the company's 2029 annual stockholder meeting or until a successor is named or he resigns or is removed earlier.¹ The filing states that Zaccardelli has not yet been placed on any board committee¹ and that there is no arrangement with any other party tied to his selection, and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.¹

Zaccardelli's background includes running his own investment firm, as he has served as Founder and Managing Member of Bull City Select Investments, LLC since 2016.¹ He also led several public pharmaceutical companies. From 2020 to 2025 he was President and CEO and a director of Verona Pharma plc, which developed ensifentrine for respiratory disease and was bought by Merck & Co. in October 2025.¹ Earlier, from 2018 to 2019, he was President and CEO and a director of Dova Pharmaceuticals, maker of the thrombocytopenia treatment Doptelet, which Sobi acquired in 2019.¹ From 2016 to 2017 he served as interim CEO and director of Cempra Pharmaceuticals, an antimicrobial-focused company later acquired by Melinta Therapeutics in 2017.¹

Under Vor's standard compensation policy, Zaccardelli will get an annual cash retainer of $40,000, paid quarterly and prorated for partial service.¹ He will also receive an initial stock option grant capped at 68,000 shares or $700,000 in grant-date value, plus future annual grants capped at 34,000 shares or $350,000, starting with the 2027 annual meeting.¹